{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:12:21Z","timestamp":1794244341472,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-00901-8","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:54:15Z","timestamp":1770616455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Akshara","family":"Singareeka Raghavendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pasyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Mouabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"901_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","volume":"147","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\u2013College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 147, 993\u20131000 (2023).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2012","unstructured":"Arteaga, C. L. et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16\u201332 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JOP.18.00206","volume":"14","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. HER2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update summary. J. Oncol. Pract. 14, 437\u2013441 (2018).","journal-title":"J. Oncol. Pract."},{"key":"901_CR4","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers13112824","volume":"13","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto, E. et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers 13, 2824 (2021).","journal-title":"Cancers"},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher, L. et al. NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J. Clin. Oncol. 38, 444 (2020).","journal-title":"J. Clin. Oncol."},{"key":"901_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"901_CR7","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","journal-title":"N. Engl. J. Med."},{"key":"901_CR8","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.3390\/cancers14153774","volume":"14","author":"H-Z Lai","year":"2022","unstructured":"Lai, H.-Z. et al. Targeted approaches to HER2-Low breast cancer: current practice and future directions. Cancers 14, 3774 (2022).","journal-title":"Cancers"},{"key":"901_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","volume":"157","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. HER2-low breast cancers: new opportunities and challenges. Am. J. Clin. Pathol. 157, 328\u2013336 (2022).","journal-title":"Am. J. Clin. Pathol."},{"key":"901_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2022.12.006","volume":"67","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. Breast 67, 1\u20137 (2023).","journal-title":"Breast"},{"key":"901_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cancers14102509","volume":"14","author":"C Domergue","year":"2022","unstructured":"Domergue, C. et al. Impact of HER2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer. Cancers 14, 2509 (2022).","journal-title":"Cancers"},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","volume":"190","author":"L de Moura Leite","year":"2021","unstructured":"de Moura Leite, L. et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res. Treat. 190, 155\u2013163 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"901_CR13","doi-asserted-by":"crossref","unstructured":"Tarantino, P. et al. Prognostic and biologic significance of ERBB2-Low expression in early-stage breast cancer. JAMA Oncol. 8, 1177\u20131183 (2022).","DOI":"10.1001\/jamaoncol.2022.2286"},{"key":"901_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01519-x","volume":"24","author":"HS Won","year":"2022","unstructured":"Won, H. S. et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 24, 22 (2022).","journal-title":"Breast Cancer Res."},{"key":"901_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906011","volume":"12","author":"H Xu","year":"2022","unstructured":"Xu, H. et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience. Front. Oncol. 12, 906011 (2022).","journal-title":"Front. Oncol."},{"key":"901_CR16","first-page":"1","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang, G. et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 20, 1\u201315 (2022).","journal-title":"BMC Med."},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert, C. et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22, 1151\u20131161 (2021).","journal-title":"Lancet Oncol."},{"key":"901_CR18","doi-asserted-by":"crossref","unstructured":"Hurvitz, S. A. et al. TRIO-US B-12 TALENT: Phase II Neoadjuvant Trial Evaluating Trastuzumab Deruxtecan With or Without Anastrozole for HER2-low, HR+ Early-stage Breast Cancer (American Society of Clinical Oncology, 2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS623"},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer, D. S. et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 9, 500\u2013510 (2023).","journal-title":"JAMA Oncol."},{"key":"901_CR20","doi-asserted-by":"crossref","unstructured":"Schettini, F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7, 1 (2021).","DOI":"10.1038\/s41523-020-00208-2"},{"key":"901_CR21","doi-asserted-by":"crossref","unstructured":"Horisawa, N. et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29, 234-241 (2022).","DOI":"10.1007\/s12282-021-01303-3"},{"key":"901_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jamaoncol.2022.5091","volume":"9","author":"V Cappelletti","year":"2023","unstructured":"Cappelletti, V., Di Cosimo, S. & Pruneri, G. Association of hormone receptors with clinical outcomes in patients with ERBB2-low breast cancer. JAMA Oncol. 9, 146\u2013147 (2023).","journal-title":"JAMA Oncol."},{"key":"901_CR23","doi-asserted-by":"crossref","unstructured":"Geukens, T. et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur. J. Cancer 188, 152-160 (2023).","DOI":"10.1016\/j.ejca.2023.04.026"},{"key":"901_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39372-3","volume":"13","author":"M Yang","year":"2023","unstructured":"Yang, M. et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci. Rep. 13, 12382 (2023).","journal-title":"Sci. Rep."},{"key":"901_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-015-3407-2","volume":"151","author":"T Ignatov","year":"2015","unstructured":"Ignatov, T. et al. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res. Treat. 151, 357\u2013364 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"901_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/ERC-15-0335","volume":"22","author":"H Eggemann","year":"2015","unstructured":"Eggemann, H. et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr.-Relat. cancer 22, 725\u2013733 (2015).","journal-title":"Endocr.-Relat. cancer"},{"key":"901_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/PAS.0b013e31819437f9","volume":"33","author":"MZ Gilcrease","year":"2009","unstructured":"Gilcrease, M. Z. et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am. J. Surg. Pathol. 33, 759 (2009).","journal-title":"Am. J. Surg. Pathol."},{"key":"901_CR28","first-page":"1445","volume":"63","author":"RL Camp","year":"2003","unstructured":"Camp, R. L. et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 63, 1445\u20131448 (2003).","journal-title":"Cancer Res."},{"key":"901_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.breast.2021.08.016","volume":"60","author":"R Mutai","year":"2021","unstructured":"Mutai, R. et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast 60, 62\u201369 (2021).","journal-title":"Breast"},{"key":"901_CR30","unstructured":"Institute NC. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973\u2014Based on the November 2015 Submission, 2016) (National Cancer Institute, 2013)."},{"key":"901_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino, P. et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann. Oncol. 34, 645\u2013659 (2023).","journal-title":"Ann. Oncol."},{"key":"901_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124\u20131135 (2019).","journal-title":"Lancet Oncol."},{"key":"901_CR33","doi-asserted-by":"publisher","first-page":"GS2-03","DOI":"10.1158\/1538-7445.SABCS22-GS2-03","volume":"83","author":"A Bardia","year":"2023","unstructured":"Bardia, A. et al. Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Cancer Res. 83, GS2-03\u2013GS2-03 (2023).","journal-title":"Cancer Res."},{"key":"901_CR34","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med 29, 2110\u20132120 (2023).","journal-title":"Nat. Med"},{"key":"901_CR35","doi-asserted-by":"publisher","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"G Curigliano","year":"2024","unstructured":"Curigliano, G. et al. Trastuzumab deruxtecan (T-DXd) vs. physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). J. Clin. Oncol. 42, LBA1000\u2013LBA1000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"901_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104979","volume":"216","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Bystander effect in antibody\u2013drug conjugates: navigating the fine line in tumor heterogeneity. Crit. Rev. Oncol. Hematol. 216, 104979 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"901_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez, A. I. et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 8, 607\u2013610 (2022).","journal-title":"JAMA Oncol."},{"key":"901_CR38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"A Wolff","year":"2018","unstructured":"Wolff, A. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"901_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1309\/MD79CDXN1D01E862","volume":"129","author":"M Brunelli","year":"2008","unstructured":"Brunelli, M. et al. HER-2\/neu assessment in breast cancer using the original FDA and New ASCO\/CAP Guideline Recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 129, 907\u2013911 (2008).","journal-title":"Am. J. Clin. Pathol."},{"key":"901_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1245\/s10434-012-2588-8","volume":"20","author":"B Deyarmin","year":"2013","unstructured":"Deyarmin, B. et al. Effect of ASCO\/CAP guidelines for determining ER status on molecular subtype. Ann. Surg. Oncol. 20, 87\u201393 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"901_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ajcp\/aqz012","volume":"152","author":"AM Gordian-Arroyo","year":"2019","unstructured":"Gordian-Arroyo, A. M., Zynger, D. L. & Tozbikian, G. H. Impact of the 2018 ASCO\/CAP HER2 Guideline Focused Update. Am. J. Clin. Pathol. 152, 17\u201326 (2019).","journal-title":"Am. J. Clin. Pathol."},{"key":"901_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","volume":"484","author":"M Ivanova","year":"2024","unstructured":"Ivanova, M. et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 484, 3\u201314 (2024).","journal-title":"Virchows Arch."},{"key":"901_CR43","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.5858\/134.7.e48","volume":"134","author":"MEH Hammond","year":"2010","unstructured":"Hammond, M. E. H. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48\u2013e72 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"901_CR44","doi-asserted-by":"crossref","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","DOI":"10.1200\/JCO.19.02309"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00901-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:10:23Z","timestamp":1773763823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00901-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00901-8","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}